<DOC>
	<DOCNO>NCT01949532</DOCNO>
	<brief_summary>The purpose study see body cancer react carfilzomib , include measure amount study drug blood certain time follow dosing . This study do people normal kidney function end-stage renal disease see respond differently study drug .</brief_summary>
	<brief_title>Study Pharmacokinetics Safety Carfilzomib Patients With Multiple Myeloma Renal Disease</brief_title>
	<detailed_description>Specifically , purpose study assess influence end-stage renal disease ( ESRD ) area curve ( area curve , time 0 last concentration measure [ AUC0-last ] area curve , time 0 extrapolated infinity [ AUC0-inf ] ) carfilzomib 56 mg/m² Cycle 2 Day 1 ( C2D1 ) patient relapse multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Key 1 . Relapsed multiple myeloma 2 . Evaluable disease ( serum protein electrophoresis [ SPEP ] /urine protein electrophoresis [ UPEP ] /serum free light chain [ SFLC ] criterion ) 3 . Received least 1 prior treatment regimen line therapy multiple myeloma 4 . Endstage renal disease ( ESRD ) hemodialysis CrCl ≥ 75 mL/min 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 6 . Adequate organ bone marrow function 7 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention myocardial infarction within protocolspecified period prior enrollment Key 1 . Immunoglobulin M ( IgM ) multiple myeloma 2 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 3 . Waldenström Macroglobulinemia 4 . Active congestive heart failure ( NYHA Class IIIIV ) ischemia , conduction abnormality 5 . Known human immunodeficiency virus ( HIV ) , recent hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) 6 . Myelodysplastic Syndrome 7 . Contraindication test article , constituent , require concomitant medication 8 . Other investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>